Looking back on 2022, Rasa Tarvydienė, the Head of Norameda’s OTC Division, notes that it has been an exceptional year for the European pharmaceutical market.
The biggest challenge was fragile supply chains and shortages of certain medicines due to a lack of production materials. And this has already become the hallmark of 2022.
“We never had a year like this before due to supply disruptions. Still, despite the unprecedented challenges, our division managed to come out with high sales results,” says R. Tarvydienė.
Based on the IQVIA report, the pandemic dominated much of the past three years. Accordingly, the pharmaceutical market faced logistical and medicine disruption in some therapy areas throughout the pandemic. It is estimated that global market growth will return to pre-pandemic projected growth rates only by 2024.
“Still, our long-standing medicines have shown nice growth last year. However, I am particularly excited about the new products introduced to the market, especially from Italian brand Aboca. We have received excellent feedback from both patients and doctors. So I think the Aboca sales and product basket will only grow,” says R. Tarvydienė.
According to the Head of Norameda’s OTC Division, offering people a good product that you know is the highest quality and helps people with various conditions is very satisfying. As of Aboca, all the products are 100% natural, some even gluten-free.
“We have Aboca products for cough and the digestive system, especially effective for dealing with reflux: both for adults and children,” says R. Tarvydienė.
Still, Aboca is only one of many. The basket of products includes brands by well-known manufacturers from all over Europe: DMG Italia, Soho Flordis UK, Verfora from Switzerland, and others.
It’s important to note, Norameda is the only representative of such brands as Perskindol®, Rinopanteina®, Equazen®, GASTROTUSS®, Emofix®, and many others in the Baltics.
“No doubt, 2023 comes with challenges. Just look at the inflation rates. Still, I’m optimistic. We have an expansive product basket, so we are looking forward to the coming year with confidence,” says R. Tarvydienė.
There is more than one reason for optimism: the launch of the updated Norameda online pharmacy and deals on new brands already on the way.
“This year, our primary focus lays on Ophthalmology. So stay tuned for exciting news,” ends the conversation the Head of Norameda’s OTC Division, Rasa Tarvydienė.